Cite
HARVARD Citation
Pozzi, S. et al. (2017). Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leukemia & lymphoma. 58 (3), pp. 552-559. [Online].